Barclays lowered the firm’s price target on Definitive Healthcare (DH) to $2.75 from $3 and keeps an Equal Weight rating on the shares following a transfer of coverage. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Definitive Healthcare price target lowered to $4 from $5 at Canaccord
- Definitive Healthcare Earnings Call: Mixed Sentiment Amid Challenges
- Definitive Healthcare Corp: Solid Q3 Results Amidst Retention Challenges Justify Hold Rating
- Definitive Healthcare price target lowered to $5 from $6 at Stifel
- Definitive Healthcare price target lowered to $3 from $4 at Baird